Surgery for advanced pancreatic neuroendocrine neoplasms: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES)
Open Access
- 31 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (2)
Abstract
Pancreatic neuroendocrine neoplasms (pNEN) comprise less than 5% of all pancreatic neoplasms. Despite their rarity, the incidence has steadily increased in both the USA and Europe over recent decades1,2. In Europe, their age-standardized incidence reached 1 per 100 000 inhabitants in 2018 and an average annual increase of 110.6% was observed2. pNEN represent a heterogeneous group of tumours, including functioning tumours secreting hormones that lead to distinct clinical syndromes, as well as non-functioning tumours with an inherent malignancy risk. pNEN are stratified into pancreatic neuroendocrine tumours (pNET) (grade 1 (G1), grade 2 (G2), and grade 3 (G3)) and pancreatic neuroendocrine carcinoma (pNEC) according to the WHO classification system3,4. The WHO 2017 classification further subdivided G3 tumours into pNET (G3) and pNEC because of genetic, clinical, histological, and prognostic differences that affect subsequent treatment3,5.Keywords
This publication has 27 references indexed in Scilit:
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- Prognostic Assessment of Non‐functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk‐Adapted Resection StrategiesWorld Journal of Surgery, 2019
- Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patientsClinics and Research in Hepatology and Gastroenterology, 2019
- Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survivalHPB, 2019
- A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastasesHPB, 2018
- Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2017
- Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liverEuropean Journal of Surgical Oncology, 2017
- Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluationEuropean Journal of Surgical Oncology, 2017
- GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strengthJournal of Clinical Epidemiology, 2013
- Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomasDigestive and Liver Disease, 2009